Core Insights - CDT Equity Inc. has announced a collaboration with Sarborg Limited to utilize an expanded rare disease signature database for mapping its asset portfolio [3][5] - Sarborg has curated a database of approximately 1,700 rare disease signatures, enhancing its existing library of over 1,600 conditions, which will facilitate rapid analysis of disease relationships and therapeutic opportunities [2][3] Company Overview - CDT Equity Inc. is a data-driven biopharmaceutical development company focused on advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [5] - The company aims to create shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [5] Collaboration Details - The collaboration with Sarborg will allow CDT to maximize its intellectual property position and explore commercialization opportunities through external partnerships [3] - CDT holds a 20% equity stake in Sarborg and continues to leverage its cross-industry signature intelligence platform [3]

Core Viewpoint - CDT Equity Inc. acknowledges the filing of a U.S. provisional patent application by Sarborg Limited for its AI Signature Agent, viewing it as a significant step in enhancing Sarborg's intellectual property position and supporting its long-term growth potential [1][3]. Group 1: Patent Filing Details - Sarborg filed a provisional patent application with the United States Patent and Trademark Office on February 12, 2026, assigned United States Patent Application No. 63/981,801 [2]. - The application pertains to Sarborg's Signature Agent architecture and its methodology for encoding and analyzing biological, chemical, and industrial signatures to produce intelligence-driven outputs [2]. Group 2: Company Perspective - As a 20% shareholder, CDT views the patent filing as a crucial milestone in the development and protection of Sarborg's proprietary technology [3]. - The advancement of Sarborg's intellectual property is believed to support the scalability of its Signature Agent across various sectors, enhancing its long-term growth profile [3]. Group 3: Company Overview - CDT Equity Inc. is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [4]. - The company aims to create shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [4].

Core Viewpoint - CDT Equity Inc. has announced a strategic transaction to acquire a 20% equity stake in Sarborg Limited, enhancing collaboration and growth opportunities for both companies [1][3][4]. Group 1: Strategic Transaction - The acquisition formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's AI capabilities [2][3]. - The total consideration for the acquisition is $115 million, to be settled through the issuance of 598,005 new common stock in CDT and 109,978,918 pre-funded warrants, pending shareholder approval [5]. Group 2: Business Synergies - Sarborg's business focuses on using biological, chemical, and industrial signatures as a universal data language to identify and generate high-value opportunities, which aligns with CDT's focus on solid-form development [2][3]. - The transaction provides CDT shareholders with exposure to Sarborg's growth beyond pharmaceuticals, allowing for broader participation in sectors where signature analysis can be applied [4]. Group 3: Leadership Perspective - Dr. Andrew Regan, CEO of CDT, emphasized that acquiring a stake in Sarborg strengthens their relationship and aligns with a business whose innovative approach is complementary to CDT's own [5].

Core Insights - CDT Equity Inc. announced the acquisition of 9.25648743 Bitcoin for a total price of $1,005,000, averaging $108,301.75 per BTC, increasing total holdings to 17.9090111 BTC [1][2] Group 1: Acquisition Details - The acquisition is part of CDT's cryptocurrency treasury reserve strategy aimed at diversifying the balance sheet and enhancing long-term shareholder value through digital asset accumulation [2][3] - The total Bitcoin holdings of CDT now amount to 17.9090111 BTC following this transaction [1] Group 2: Strategic Intent - CDT's CFO emphasized a disciplined and opportunistic approach to capital management, aligning with the growing institutional adoption of digital assets and aiming to strengthen financial resilience [3] - The company is committed to strategically deploying capital within its treasury reserve program, focusing initially on Bitcoin [3] Group 3: Company Overview - CDT Equity Inc. is a biopharmaceutical development company that leverages scientific innovation and strategic partnerships to advance therapeutic assets [3] - The company has evolved from Conduit Pharmaceuticals to a broader platform utilizing artificial intelligence and efficient asset repositioning for novel treatment development [3]